Hypertension in the Hemodialysis Patient and the "Lag Phenomenon": Insights into Pathophysiology and Clinical Management

American Journal of Kidney Diseases

Volumn 43, Issue 4, 2004, Pages 739-751

  Khosla, Uday M ^a   Johnson, Richard J ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD PRESSURE REGULATION; EDITORIAL; EXTRACELLULAR SPACE; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; PATHOPHYSIOLOGY; SODIUM RETENTION; SYSTOLIC BLOOD PRESSURE;

EID: 1642422861     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2003.12.036     Document Type: Article

References (121)

1. Rocco MV, Yan G, Heyka RJ, Benz R, Cheung AK: Risk factors for hypertension in chronic hemodialysis patients: Baseline data from the HEMO study. Am J Nephrol 21:280-288, 2001
2. Vertes V, Cangiano JL, Berman LB, Gould A: Hypertension in end-stage renal disease. N Engl J Med 280:978-981, 1969
3. Sellars L, Robson V, Wilkinson R: Sodium retention and hypertension with short dialysis. Br Med J 1:520-521, 1979
4. Wizemann V, Kramer W: Short-term dialysis-long-term complications. Ten years experience with short-duration renal replacement therapy. Blood Purif 5:193-201, 1987
5. Grekas D, Bamichas G, Bacharaki D, Goutzaridis N, Kasimatis E, Tourkantonis A: Hypertension in chronic hemodialysis patients: Current view on pathophysiology and treatment. Clin Nephrol 53:164-168, 2000
6. Rahman M, Dixit A, Donley V, et al: Factors associated with inadequate blood pressure control in hypertensive hemodialysis patients. Am J Kidney Dis 33:498-506, 1999
7. Cheigh JS, Milite C, Sullivan JF, Rubin AL, Stenzel KH: Hypertension is not adequately controlled in hemodialysis patients. Am J Kidney Dis 19:453-459, 1992
8. Horl MP, Horl WH: Hemodialysis-associated hypertension: Pathophysiology and therapy. Am J Kidney Dis 39:227-244, 2002
9. Kong CH, Farrington K: Determinants of left ventricular hypertrophy and its progression in high-flux haemodialysis. Blood Purif 21:163-169, 2003
10. Stack AG, Saran R: Clinical correlates and mortality impact of left ventricular hypertrophy among new ESRD patients in the United States. Am J Kidney Dis 40:1202-1210, 2002
11. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27:347-354, 1996
12. Levey AS, Beto JA, Coronado BE, et al: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 32:853-906, 1998
13. Tucker B, Fabbian F, Giles M, Thuraisingham RC, Raine AE, Baker LR: Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial Transplant 12:724-728, 1997
14. Savazzi GM, Cusmano F, Bergamaschi E, Vinci S, Allegri L, Garini G: Hypertension as an etiopathological factor in the development of cerebral atrophy in hemodialyzed patients. Nephron 81:17-24, 1999
15. Seliger SL, Gillen DL, Tirschwell D, Wasse H, Kestenbaum BR, Stehman-Breen CO: Risk factors for incident stroke among patients with end-stage renal disease. J Am Soc Nephrol 14:2623-2631, 2003
16. Agarwal R: Assessment of blood pressure in hemodialysis patients. Semin Dial 15:299-304, 2002
17. Verdecchia P, Schillaci G, Guerrieri M, et al: Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 81:528-536, 1990
18. Farmer CK, Goldsmith DJ, Cox J, Dallyn P, Kingswood JC, Sharpstone P: An investigation of the effect of advancing uraemia, renal replacement therapy and renal transplantation on blood pressure diurnal variability. Nephrol Dial Transplant 12:2301-2307, 1997
19. Devereux RB, Pickering TG: Relationship between the level, pattern and variability of ambulatory blood pressure and target organ damage in hypertension. J Hypertens Suppl 9:S34-38, 1991
20. Verdecchia P, Schillaci G, Borgioni C, et al: Altered circadian blood pressure profile and prognosis. Blood Press Monit 2:347-352, 1997
21. O'Brien E, Sheridan J, O'Malley K: Dippers and non-dippers. Lancet 2:397, 1988
22. Izzo JL Jr, Levy D, Black HR: Clinical advisory statement. Importance of systolic blood pressure in older Americans. Hypertension 35:1021-1024, 2000
23. Chobanian AV, Bakris GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289:2560-2572, 2003 (erratum 290:197, 2003)
24. Klassen PS, Lowrie EG, Reddan DN, et al: Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 287:1548-1555, 2002
25. Agarwal R: Systolic hypertension in hemodialysis patients. Semin Dial 16:208-213, 2003
26. Murphy RJF: The effect of "rice diet" on plasma volume and extracellular fluid space in hypertensive subjects. J Clin Invest 29:912-917, 1950
27. Dahl LK, Heine M: Primary role of renal homografts in setting chronic blood pressure levels in rats. Circ Res 36:692-696, 1975
28. Dahl LK, Knudsen KD, Heine M, Leitl G: Effects of chronic excess salt ingestion. Genetic influence on the development of salt hypertension in parabiotic rats: Evidence for a humoral factor. J Exp Med 126:687-699, 1967
29. Blumberg A, Nelp WB, Hegstrom RM, Scribner BH: Extracellular volume in patients with chronic renal disease treated for hypertension by sodium restriction. Lancet 2:69-73, 1967
30. Massry SG, Iseki K, Campese VM: Serum calcium, parathyroid hormone, and blood pressure. Am J Nephrol 6:19-28, 1986 (suppl 1)
31. Kennedy BP, Farag NH, Ziegler MG, Mills PJ: Relationship of systolic blood pressure with plasma homocysteine: Importance of smoking status. J Hypertens 21:1307-1312, 2003
32. Odar-Cederlof I, Ericsson F, Theodorsson E, Kjellstrand CM: Is neuropeptide Y a contributor to volume-induced hypertension? Am J Kidney Dis 31:803-808, 1998
33. Mazzali M, Hughes J, Kim YG, et al: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38:1101-1106, 2001
34. Dolson GM, Ellis KJ, Bernardo MV, Prakash R, Adrogue HJ: Acute decreases in serum potassium augment blood pressure. Am J Kidney Dis 26:321-326, 1995
35. Jaeger JQ, Mehta RL: Assessment of dry weight in hemodialysis: An overview. J Am Soc Nephrol 10:392-403, 1999
36. Charra B, Laurent G, Chazot C, et al: Clinical assessment of dry weight. Nephrol Dial Transplant 11: 16-19, 1996 (suppl 2)
37. Charra B, Chazot C: Volume control, blood pressure and cardiovascular function. Lessons from hemodialysis treatment. Nephron Physiol 93:94-101, 2003
38. Laurent G: How to keep the dialysis patients normotensive? What is the secret of Tassin? Nephrol Dial Transplant 12:1104, 1997
39. Charra B, Bergstrom J, Scribner BH: Blood pressure control in dialysis patients: Importance of the lag phenomenon. Am J Kidney Dis 32:720-724, 1998
40. Katzarski KS, Nisell J, Randmaa I, Danielsson A, Freyschuss U, Bergstrom J: A critical evaluation of ultrasound measurement of inferior vena cava diameter in assessing dry weight in normotensive and hypertensive hemodialysis patients. Am J Kidney Dis 30:459-465, 1997
41. Scribner BH, Buri R, Caner JE, Hegstrom R, Burnell JM: The treatment of chronic uremia by means of intermittent hemodialysis: A preliminary report. 1960. Trans Am Soc Artif Intern Organs 6:114-119, 1960
42. Innes A, Charra B, Burden RP, Morgan AG, Laurent G: The effect of long, slow haemodialysis on patient survival. Nephrol Dial Transplant 14:919-922, 1999
43. Charra B, Calemard E, Ruffet M, et al: Survival as an index of adequacy of dialysis. Kidney Int 41:1286-1291, 1992
44. Leth A, Ibsen H: Changes in the ratio of plasma to intersitiial fluid volume during long-term antihypertensive therapy. J Lab Clin Med 87:781-791, 1976
45. Guyton AC, Coleman TG, Cowley AV Jr, Scheel KW, Manning RD Jr, Norman RA Jr: Arterial pressure regulation. Overriding dominance of the kidneys in long-term regulation and in hypertension. Am J Med 52:584-594, 1972
46. Guyton AC: Renal function curve - A key to understanding the pathogenesis of hypertension. Hypertension 10:1-6, 1987
47. Borst JGG: Hypertension explained by Starling's Theory of Circulatory Homeostasis. Lancet 1:677-682, 1963
48. Ozkahya M, Toz H, Unsal A, et al: Treatment of hypertension in dialysis patients by ultrafiltration: Role of cardiac dilatation and time factor. Am J Kidney Dis 34:218-221, 1999
49. Luik AJ, van Kuijk WH, Spek J, et al: Effects of hypervolemia on interdialytic hemodynamics and blood pressure control in hemodialysis patients. Am J Kidney Dis 30:466-474, 1997
50. Chazot C, Charra B, Vo Van C, et al: The Janus-faced aspect of "dry weight". Nephrol Dial Transplant 14:121-124, 1999
51. Knudsen KD, Iwai J, Heine M, Leitl G, Dahl LK: Genetic influence on the development of renoprival hypertension in parabiotic rats. Evidence that a humoral hypertensinogenic factor is produced in kidney tissue of hypertension-prone rats. J Exp Med 130:1353-1365, 1969
52. +)ATPase associated with essential hypertension. Nature 300:650-652, 1982
53. Blaustein MP, Hamlyn JM: Pathogenesis of essential hypertension. A link between dietary salt and high blood pressure. Hypertension 18:111184-195, 1991
54. de Wardener HE: The hypothalamus and hypertension. Physiol Rev 81:1599-1658, 2001
55. Lee J, de Wardener HE: Neurosecretion and sodium excretion. Kidney Int 6:323-330, 1974
56. Takahashi H, Matsuzawa M, Okabayashi H, et al: Evidence for a digitalis-like substance in the hypothalamopituitary axis in rats: Implications in the central cardiovascular regulation associated with an excess intake of sodium. Jpn Circ J 51:1199-1207, 1987
57. Takahashi H, Matsusawa M, Suga K, et al: Hypothalamic digitalis-like substance is released with sodium-loading in rats. Am J Hypertens 1: 146-151, 1988
58. Hamlyn JM, Blaustein MP, Bova S, et al: Identification and characterization of a ouabain-like compound from human plasma. Proc Natl Acad Sci U S A 88:6259-6263, 1991
59. Schoner W: Endogenous cardiac glycosides, a new class of steroid hormones. Eur J Biochem 269:2440-2448, 2002
60. Yamada K, Goto A, Nagoshi H, Terano Y, Omata M: Elevation of ouabainlike compound levels with hypertonic sodium chloride load in rat plasma and tissues. Hypertension 30:94-98, 1997
61. Leenen FH, Harmsen E, Yu H: Dietary sodium and central vs. peripheral ouabain-like activity in Dahl salt-sensitive vs. salt-resistant rats. Am J Physiol 267:H1916-1920, 1994
62. Takahashi H, Matsusawa M, Nishimura M, Ikegaki I, Nakanishi T, Yoshimura M: Digoxin-like immunoreactivity increases with intravenous infusion of saline in rats. Clin Exp Pharmacol Physiol 18:505-508, 1991
63. Kramer HJ, Heppe M, Pennig J, et al: Relation of endogenous digoxin-like immunoreacting activities to salt balance and renal function in man. Klin Wochenschr 63:107-110, 1985 (suppl 3)
64. Krep H, Price DA, Soszynski P, Tao QF, Graves SW, Hollenberg NK: Volume sensitive hypertension and the digoxin-like factor. Reversal by a Fab directed against digoxin in DOCA-salt hypertensive rats. Am J Hypertens 8:921-927, 1995
65. Fedorova OV, Talan MI, Agalakova NI, Lakatta EG, Bagrov AY: Endogenous ligand of alpha(1) sodium pump, marinobufagenin, is a novel mediator of sodium chloride-dependent hypertension. Circulation 105:1122-1127, 2002
66. Mason DT, Braunwald E: Studies on digitalis, X: Effects of ouabain on forearm vascular resistance and venous tone in normal subjects and in patients in heart failure. J Clin Invest 43:532-543, 1964
67. Ferrandi M, Manunta P, Rivera R, Bianchi G, Ferrari P: Role of the ouabain-like factor and Na-K pump in rat and human genetic hypertension. Clin Exp Hypertens 20:629-639, 1998
68. Berendes E, Cullen P, Van Aken H, et al: Endogenous glycosides in critically ill patients. Crit Care Med 31:1331-1337, 2003
69. Olivero JJ: A series of hospitalized patients with elevated digoxin levels. Am J Med 106:489, 1999
70. Bisordi JE, Holt S: Digitalislike immunoreactive substances and extracellular fluid volume status in chronic hemodialysis patients. Am J Kidney Dis 13:396-403, 1989
71. Sohn HJ, Stokes GS, Johnston H: An Na, K ATPase inhibitor from ultrafiltrate obtained by hemodialysis of patients with uremia. J Lab Clin Med 120:264-271, 1992
72. Wang H, Yuan WQ, Lu ZR: Differential regulation of the sodium pump alpha-subunit isoform gene by ouabain and digoxin in tissues of rats. Hypertens Res 23:S55-60, 2000 (suppl)
73. Cheng JW, Charland SL, Shaw LM, et al: Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay. Pharmacotherapy 17:584-590, 1997
74. Hauptman PJ, Kelly RA: Digitalis, Circulation 99: 1265-1270, 1999
75. Caspi O, Zylber-Katz E, Gotsman O, Wolf DG, Caraco Y: Digoxin intoxication in a patient with end-stage renal disease: Efficacy of digoxin-specific Fab antibody fragments and peritoneal dialysis. Ther Drug Monit 19:510-515, 1997
76. Marin K DG: Critical care and medical emergencies, in Ewald GA (ed): Manual of Medical Therapeutics, Vol 9 (ed 28). Boston, Little, Brown, 1995, pp 231-232
77. Antman EM, Wenger TL, Butler VP Jr, Haber E, Smith TW: Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation 81: 1744-1752, 1990
78. Baylis C, Mitruka B, Deng A: Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. J Clin Invest 90:278-281, 1992
79. Baylis C, Vallance P: Nitric oxide and blood pressure: Effects of nitric oxide deficiency. Curr Opin Nephrol Hypertens 5:80-88, 1996
80. Bode-Boger SM, Boger RH, Kielstein JT, Loffler M, Schaffer J, Frolich JC: Role of endogenous nitric oxide in circadian blood pressure regulation in healthy humans and in patients with hypertension or atherosclerosis. J Investig Med 48:125-132, 2000
81. Vallance P, Leone A, Calver A, Collier J, Moncada S: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339:572-575, 1992
82. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E: Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 11:2449-2452, 1996
83. Kielstein JT, Boger RH, Bode-Boger SM, et al: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10:594-600, 1999
84. Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K: Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: Modulation of nitric oxide synthesis by salt intake. Circulation 101:856-861, 2000
85. Savvidou MD, Hingorani AD, Tsikas D, Frolich JC, Vallance P, Nicolaides KH: Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet 361:1511-1517, 2003
86. Scuteri A, Stuehlinger MC, Cooke JP, et al: Nitric oxide inhibition as a mechanism for blood pressure increase during salt loading in normotensive postmenopausal women. J Hypertens 21:1339-1346, 2003
87. Osanai T, Fujiwara N, Saitoh M, et al: Relationship between salt intake, nitric oxide and asymmetric dimethyl-arginine and its relevance to patients with end-stage renal disease. Blood Purif 20:466-468, 2002
88. Kielstein JT, Bode-Boger SM, Frolich JC, Haller H, Boger RH: Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int Suppl 78:S9-13, 2001
89. Fleck C, Janz A, Schweitzer F, Karge E, Schwertfeger M, Stein G: Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in renal failure patients. Kidney Int Suppl 78:S14-18, 2001
90. Schroder M, Riedel E, Beck W, Deppisch RM, Pommer W: Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes. Kidney Int Suppl 78:S19-24, 2001
91. Achan V, Broadhead M, Malaki M, et al: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 23:1455-1459, 2003
92. Lin KY, Ito A, Asagami T, et al: Impaired nitric oxide synthase pathway in diabetes mellitus: Role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106:987-992, 2002
93. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP: Novel mechanism for endothelial dysfunction: Dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99:3092-3095, 1999
94. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP: Homocysteine impairs the nitric oxide synthase pathway: Role of asymmetric dimethylarginine. Circulation 104:2569-2575, 2001
95. Tojo A, Kimoto M, Wilcox CS: Renal expression of constitutive NOS and DDAH: Separate effects of salt intake and angiotensin. Kidney Int 58:2075-2083, 2000
96. Fishbane SA, Scribner BH: Blood pressure control in dialysis patients. Semin Dial 15:144-145, 2002
97. Ozkahya M, Toz H, Qzerkan F, et al: Impact of volume control on left ventricular hypertrophy in dialysis patients. J Nephrol 15:655-660, 2002
98. Krautzig S, Janssen U, Koch KM, Granolleras C, Shaldon S: Dietary salt restriction and reduction of dialysate sodium to control hypertension in maintenance haemodialysis patients. Nephrol Dial Transplant 13:552-553, 1998
99. Agarwal R, Lewis R, Davis JL, Becker B: Lisinopril therapy for hemodialysis hypertension: Hemodynamic and endocrine responses. Am J Kidney Dis 38:1245-1250, 2001
100. Ozkahya M, Ok E, Cirit M, et al: Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant 13:1489-1493, 1998
101. Converse RL Jr, Jacobsen TN, Jost CM, et al: Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis-induced hypotension. J Clin Invest 90:1657-1665, 1992
102. Katzarski KS, Charra B, Luik AJ, et al: Fluid state and blood pressure control in patients treated with long and short haemodialysis. Nephrol Dial Transplant 14:369-375, 1999
103. Wizemann V, Leibinger A, Mueller K, Nilson A: Influence of hydration state on plasma volume changes during ultrafiltration. Artif Organs 19:416-419, 1995
104. Katzarski K, Charra B, Laurent G, et al: Multifrequency bioimpedance in assessment of dry weight in haemodialysis. Nephrol Dial Transplant 11:20-23, 1996 (suppl 2)
105. Cheriex EC, Leunissen KM, Janssen JH, Mooy JM, van Hooff JP: Echography of the inferior vena cava is a simple and reliable tool for estimation of "dry weight" in haemodialysis patients. Nephrol Dial Transplant 4:563-568, 1989
106. Hirayama S, Ando Y, Sudo Y, Asano Y: Improvement of cardiac function by dry weight optimization based on interdialysis inferior vena caval diameter. Asaio J 48:320-325, 2002
107. Tetsuka T, Ando Y, Ono S, Asano Y: Change in inferior vena caval diameter detected by ultrasonography during and after hemodialysis. ASAIO J 41:105-110, 1995
108. Cooper BA, Aslani A, Ryan M, et al: Comparing different methods of assessing body composition in endstage renal failure. Kidney Int 58:408-416, 2000
109. Cha K, Chertow GM, Gonzalez J, Lazarus JM, Wilmore DW: Multifrequency bioelectrical impedance estimates the distribution of body water. J Appl Physiol 79:1316-1319, 1995
110. Chamney PW, Kramer M, Rode C, Kleinekofort W, Wizemann V: A new technique for establishing dry weight in hemodialysis patients via whole body bioimpedance. Kidney Int 61:2250-2258, 2002
111. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S: Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 30:659-664, 1997
112. Efrati S, Zaidenstein R, Dishy V, et al: ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 40:1023-1029, 2002
113. Kosman ME: Evaluation of a new antihypertensive agent. Minoxidil. JAMA 244:73-75, 1980
114. Shirwany A, D'Cruz IA, Munir A: Very large pericardial effusion attributable to minoxidil: Resolution without drainage of fluid. Echocardiography 19:513-516, 2002
115. Lacson E Jr, Diaz-Buxo JA: Daily and nocturnal hemodialysis: How do they stack up? Am J Kidney Dis 38:225-239, 2001
116. Pierratos A: Nocturnal home haemodialysis: An update on a 5-year experience. Nephrol Dial Transplant 14:2835-2840, 1999
117. Fagugli RM, Reboldi G, Quintaliani G, et al: Short daily hemodialysis: Blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis 38:371-376, 2001
118. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A: Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 61:2235-2239, 2002
119. Eknoyan G, Beck GJ, Cheung AK, et al: Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347:2010-2019, 2002
120. Charra B, Laurent G, Chazot C, Jean G, Terrat JC, Vanel T: Hemodialysis trends in time, 1989 to 1998, independent of dose and outcome. Am J Kidney Dis 32:S63-S70, 1998 (suppl 4)
121. Velasquez MT, von Albertini B, Lew SQ, Mishkin GJ, Bosch JP: Equal levels of blood pressure control in ESRD patients receiving high-efficiency hemodialysis and conventional hemodialysis. Am J Kidney Dis 31:618-623, 1998